newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Aligos Therapeutics (NASDAQ: ALGS) granted non-qualified stock options to newly hired employees on November 11, 2025.
  • The aggregate Inducement Grant covers 23,600 shares of company stock.
  • Grants were issued under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The exercise price per share equals the closing price of Aligos' common stock on the grant date.
  • Shares vest over a four-year period, with 25% vesting on the first anniversary and the remainder in equal monthly installments.
  • Vesting is subject to continued employment through the applicable dates.
  • Aligos is a clinical stage biopharmaceutical company developing therapies for liver diseases, viral infections, obesity, MASH, \& coronaviruses.